Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics


Marker Therapeutics, Inc. (MRKR)

Today's Latest Price: $2.04 USD

0.01 (-0.49%)

Updated Jan 25 6:55pm

Add MRKR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

MRKR Stock Summary

  • MRKR's price/sales ratio is 144.79; that's higher than the P/S ratio of 97.03% of US stocks.
  • With a year-over-year growth in debt of 2,195.11%, Marker Therapeutics Inc's debt growth rate surpasses 98.99% of about US stocks.
  • As for revenue growth, note that MRKR's revenue has grown 218.95% over the past 12 months; that beats the revenue growth of 97.18% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Marker Therapeutics Inc, a group of peers worth examining would be ACRS, BCDA, RESN, XAIR, and APTX.
  • MRKR's SEC filings can be seen here. And to visit Marker Therapeutics Inc's official web site, go to www.markertherapeutics.com.

MRKR Stock Price Chart Interactive Chart >

Price chart for MRKR

MRKR Price/Volume Stats

Current price $2.04 52-week high $3.35
Prev. close $2.05 52-week low $1.32
Day low $1.98 Volume 252,700
Day high $2.05 Avg. volume 767,720
50-day MA $1.68 Dividend yield N/A
200-day MA $1.86 Market Cap 97.97M

Marker Therapeutics, Inc. (MRKR) Company Bio


Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.


MRKR Latest News Stream


Event/Time News Detail
Loading, please wait...

MRKR Latest Social Stream


Loading social stream, please wait...

View Full MRKR Social Stream

Latest MRKR News From Around the Web

Below are the latest news stories about Marker Therapeutics Inc that investors may wish to consider to help them evaluate MRKR as an investment opportunity.

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport. The facility will allow production of MultiTAA-specific T cell products according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The Company has initiated the technology transfer process and expects the cGMP manufacturing facility to be fully operational in the first half of 2021.

Yahoo | January 13, 2021

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the Company's Phase 2 trial investigating the safety and efficacy of MT-401, Marker's lead multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia (AML).

Yahoo | January 5, 2021

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 30, 2020

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

Yahoo | November 9, 2020

Marker Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Marker Therapeutics, Inc.

Yahoo | November 9, 2020

Read More 'MRKR' Stories Here

MRKR Price Returns

1-mo N/A
3-mo 42.66%
6-mo 3.55%
1-year -29.90%
3-year -46.32%
5-year -70.99%
YTD 40.69%
2020 -49.65%
2019 -48.11%
2018 41.58%
2017 1.03%
2016 -46.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8997 seconds.